FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine, namely neurology, and is intended for use in the treatment of epileptic encephalopathy. The composition for increasing compliance with the ketogenic diet by a patient diagnosed with refractory epilepsy contains fenfluramine hydrochloride, sodium methylparaben, sodium ethylparaben, sucralose, hydroxyethyl cellulose, flavor, potassium citrate monohydrate, citric acid monohydrate and water. The components are used in the stated quantities. A method for increasing compliance with the ketogenic diet is also presented, including administration to the patient, over a period of several days, of the specified composition. In other embodiments, methods for treating a patient with a diagnosis of epileptic encephalopathy are presented.
EFFECT: use of the group of inventions makes it possible to increase the effectiveness of the treatment of epileptic encephalopathy and/or seizures experienced by patients with Dravet syndrome, Lennox-Gastaut syndrome or Doose syndrome who are on a ketogenic diet.
42 cl, 12 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF DOOSE SYNDROME, USING FENFLURAMINE | 2018 |
|
RU2784524C2 |
| COMPOSITION FOR INHIBITING SYNTHESIS OF 5-HT2B AGONIST AND METHODS OF USE THEREOF | 2017 |
|
RU2746000C2 |
| METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE | 2016 |
|
RU2740919C2 |
| PHARMACEUTICAL DRUG | 2019 |
|
RU2795027C2 |
| CONTROL SYSTEM FOR MANAGING DISTRIBUTION OF MEDICINAL PRODUCTS | 2015 |
|
RU2704749C2 |
| LIQUID DOSAGE FORM FOR ORAL ADMINISTRATION, HAVING NOOTROPIC ACTIVITY | 2018 |
|
RU2703293C1 |
| 3-[1,2,3,6-TETRAHYDROPYRIDIN-2-YL]PYRIDINE GLUTARATE OR PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | 2019 |
|
RU2823979C2 |
| METHODS OF TREATING DRAVET SYNDROME | 2018 |
|
RU2767661C2 |
| DERIVATIVE PYRIDOXIN FOR TREATMENT OF EPILEPSY | 2017 |
|
RU2650523C1 |
| USE OF CARBAMATE DERIVATIVE FOR PREVENTION, RELIEF, OR TREATMENT OF MINOR EPILEPTIC SEIZURE OR EPILEPSY SHOWING MINOR EPILEPTIC SEIZURE | 2018 |
|
RU2787771C2 |
